BRPI0909227A2 - uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin. - Google Patents

uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin.

Info

Publication number: BRPI0909227A2
Authority: BR; Brazil
Prior art keywords: antibody; adcc; lymphomas; vincristine; hodgkin
Prior art date: 2008-03-25

Application number

BRPI0909227A

Other languages

English (en)

Inventor

Charles Dumontet

Christian Klein

Frank Herting

Pablo Umana

Thomas Friess

Original Assignee

Roche Glycart Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-25

Filing date

2009-03-23

Publication date

2015-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40872445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909227(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-23 Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag

2015-12-01 Publication of BRPI0909227A2 publication Critical patent/BRPI0909227A2/pt

2020-11-24 Publication of BRPI0909227B1 publication Critical patent/BRPI0909227B1/pt

2021-05-25 Publication of BRPI0909227B8 publication Critical patent/BRPI0909227B8/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0909227A 2008-03-25 2009-03-23 uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl) BRPI0909227B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP08005554.4		2008-03-25
EP08005554		2008-03-25
EP08007172.3		2008-04-11
EP08007172		2008-04-11
PCT/EP2009/002111 WO2009118142A1 (en)	2008-03-25	2009-03-23	Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas

Publications (3)

Publication Number	Publication Date
BRPI0909227A2 true BRPI0909227A2 (pt)	2015-12-01
BRPI0909227B1 BRPI0909227B1 (pt)	2020-11-24
BRPI0909227B8 BRPI0909227B8 (pt)	2021-05-25

Family

ID=40872445

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0909227A BRPI0909227B8 (pt)	2008-03-25	2009-03-23	uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)

Country Status (31)

Country	Link
US (6)	US20090246197A1 (pt)
EP (1)	EP2268310B1 (pt)
JP (3)	JP5547709B2 (pt)
KR (1)	KR101280716B1 (pt)
CN (2)	CN107198772A (pt)
AR (1)	AR072947A1 (pt)
AU (1)	AU2009228616B2 (pt)
BR (1)	BRPI0909227B8 (pt)
CA (1)	CA2716884C (pt)
CL (1)	CL2009000713A1 (pt)
CR (1)	CR11687A (pt)
CY (1)	CY1117984T1 (pt)
DK (1)	DK2268310T3 (pt)
ES (1)	ES2592312T3 (pt)
HR (1)	HRP20161301T1 (pt)
HU (1)	HUE028828T2 (pt)
IL (1)	IL208018A (pt)
LT (1)	LT2268310T (pt)
MA (1)	MA32140B1 (pt)
MX (1)	MX2010009647A (pt)
MY (1)	MY163544A (pt)
NZ (1)	NZ587284A (pt)
PE (1)	PE20091821A1 (pt)
PL (1)	PL2268310T3 (pt)
PT (1)	PT2268310T (pt)
RS (1)	RS55258B1 (pt)
RU (1)	RU2589704C2 (pt)
SI (1)	SI2268310T1 (pt)
TW (1)	TWI500624B (pt)
WO (1)	WO2009118142A1 (pt)
ZA (1)	ZA201006190B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2961563B2 (ja)	1991-01-29	1999-10-12	株式会社トーキン	パルス発生用磁気ワイヤの製造方法
ES2672640T3 (es)	2003-11-05	2018-06-15	Roche Glycart Ag	Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
MY163544A (en) *	2008-03-25	2017-09-29	Roche Glycart Ag	Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas
TW201438738A (zh)	2008-09-16	2014-10-16	建南德克公司	治療進展型多發性硬化症之方法
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CA3007787C (en)	2010-06-03	2020-03-10	Pharmacyclics Llc	The use of inhibitors of bruton's tyrosine kinase (btk)
CN103261229A (zh) *	2010-12-16	2013-08-21	罗切格利卡特公司	无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法
KR20250086805A (ko) *	2011-10-19	2025-06-13	파마싸이클릭스 엘엘씨	브루톤 티로신 인산화효소(btk)의 억제제의 용도
US20130302274A1 (en) *	2011-11-25	2013-11-14	Roche Glycart Ag	Combination therapy
CA2879570A1 (en)	2012-07-24	2014-01-30	Pharmacyclics, Inc.	Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
MX2016007885A (es) *	2013-12-17	2017-01-11	Genentech Inc	Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
US9732154B2 (en)	2014-02-28	2017-08-15	Janssen Biotech, Inc.	Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) *	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
EP3191187B1 (en)	2014-09-09	2021-07-28	Janssen Biotech, Inc.	Combination therapies with anti-cd38 antibodies
JP6802791B2 (ja)	2014-12-04	2020-12-23	ヤンセンバイオテツク，インコーポレーテツド	急性骨髄性白血病の治療のための抗ｃｄ３８抗体
IL303972A (en)	2015-04-08	2023-08-01	Novartis Ag	CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
BR112017024877A2 (pt)	2015-05-20	2019-09-17	Janssen Biotech, Inc.	anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
NZ777133A (en)	2015-06-22	2025-05-02	Janssen Biotech Inc	Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en)	2015-06-24	2017-02-16	Janssen Biotech, Inc.	Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en)	2015-11-03	2020-09-22	Janssen Biotech, Inc.	Subcutaneous formulations of anti-CD38 antibodies and their uses
MD3827845T2 (ro)	2015-11-03	2022-09-30	Janssen Biotech Inc	Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
CN108603037B (zh) *	2015-12-10	2020-11-17	希望之城	细胞穿透花青偶联抗体
US20190233533A1 (en)	2016-06-28	2019-08-01	Umc Utrecht Holding B.V.	Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
MY200337A (en)	2016-10-07	2023-12-20	Novartis Ag	Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
CA3046489A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en)	2017-03-30	2021-05-13	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
MA50514A (fr)	2017-10-31	2020-09-09	Janssen Biotech Inc	Méthodes de traitement du myélome multiple à haut risque
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
CN116726361A (zh)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
US20240050562A1 (en) *	2019-10-04	2024-02-15	Chugai Seiyaku Kabushiki Kaisha	Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
WO2021119482A1 (en)	2019-12-13	2021-06-17	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IL312692A (en)	2021-11-16	2024-07-01	Genentech Inc	Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2434961T5 (es) *	1998-04-20	2018-01-18	Roche Glycart Ag	Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
RU2306952C2 (ru) *	2001-01-31	2007-09-27	Байоджен Айдек Инк.	Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
PL216630B1 (pl) *	2002-10-17	2014-04-30	Genmab As	Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
ES2347241T3 (es) *	2002-12-16	2010-10-27	Genentech, Inc.	Variantes de inmunoglobulina y sus utilizaciones.
ES2672640T3 (es) *	2003-11-05	2018-06-15	Roche Glycart Ag	Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US20070014720A1 (en) *	2005-06-02	2007-01-18	Gadi Gazit-Bornstein	Antibodies directed to CD20 and uses thereof
TWI478940B (zh) *	2005-08-26	2015-04-01	Roche Glycart Ag	具有經改變細胞傳訊活性之改質抗原結合分子
MX2010002406A (es) *	2007-09-05	2010-04-27	Hoffmann La Roche	Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
MY163544A (en) *	2008-03-25	2017-09-29	Roche Glycart Ag	Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas

2009
- 2009-03-23 MY MYPI2010004461A patent/MY163544A/en unknown
- 2009-03-23 PT PT97238083T patent/PT2268310T/pt unknown
- 2009-03-23 HR HRP20161301TT patent/HRP20161301T1/hr unknown
- 2009-03-23 AU AU2009228616A patent/AU2009228616B2/en active Active
- 2009-03-23 CN CN201611215290.7A patent/CN107198772A/zh active Pending
- 2009-03-23 WO PCT/EP2009/002111 patent/WO2009118142A1/en not_active Ceased
- 2009-03-23 EP EP09723808.3A patent/EP2268310B1/en active Active
- 2009-03-23 ES ES09723808.3T patent/ES2592312T3/es active Active
- 2009-03-23 KR KR1020107021332A patent/KR101280716B1/ko active Active
- 2009-03-23 PL PL09723808T patent/PL2268310T3/pl unknown
- 2009-03-23 LT LTEP09723808.3T patent/LT2268310T/lt unknown
- 2009-03-23 RU RU2010143454/15A patent/RU2589704C2/ru active
- 2009-03-23 BR BRPI0909227A patent/BRPI0909227B8/pt active IP Right Grant
- 2009-03-23 JP JP2011501133A patent/JP5547709B2/ja active Active
- 2009-03-23 RS RS20160864A patent/RS55258B1/sr unknown
- 2009-03-23 CL CL2009000713A patent/CL2009000713A1/es unknown
- 2009-03-23 AR ARP090101035A patent/AR072947A1/es unknown
- 2009-03-23 CA CA2716884A patent/CA2716884C/en active Active
- 2009-03-23 US US12/408,746 patent/US20090246197A1/en not_active Abandoned
- 2009-03-23 SI SI200931530A patent/SI2268310T1/sl unknown
- 2009-03-23 TW TW098109412A patent/TWI500624B/zh active
- 2009-03-23 HU HUE09723808A patent/HUE028828T2/en unknown
- 2009-03-23 CN CN2009801101810A patent/CN101983071A/zh active Pending
- 2009-03-23 NZ NZ587284A patent/NZ587284A/en unknown
- 2009-03-23 DK DK09723808.3T patent/DK2268310T3/en active
- 2009-03-23 MX MX2010009647A patent/MX2010009647A/es active IP Right Grant
- 2009-03-24 PE PE2009000437A patent/PE20091821A1/es not_active Application Discontinuation
2010
- 2010-05-10 US US12/777,141 patent/US20100310581A1/en not_active Abandoned
- 2010-08-30 ZA ZA2010/06190A patent/ZA201006190B/en unknown
- 2010-09-03 MA MA33145A patent/MA32140B1/fr unknown
- 2010-09-06 IL IL208018A patent/IL208018A/en active IP Right Grant
- 2010-09-23 CR CR11687A patent/CR11687A/es unknown
2011
- 2011-03-07 US US13/042,305 patent/US20110177067A1/en not_active Abandoned
- 2011-10-28 US US13/284,415 patent/US20120301459A1/en not_active Abandoned
2013
- 2013-03-14 US US13/829,409 patent/US20140065134A1/en not_active Abandoned
2014
- 2014-01-24 JP JP2014011332A patent/JP5912142B2/ja active Active
- 2014-06-05 US US14/297,478 patent/US20160000911A1/en not_active Abandoned
2016
- 2016-03-18 JP JP2016055096A patent/JP6154039B2/ja active Active
- 2016-09-07 CY CY20161100889T patent/CY1117984T1/el unknown

Also Published As

Publication number	Publication date
JP2014101370A (ja)	2014-06-05
AU2009228616B2 (en)	2014-07-24
JP5547709B2 (ja)	2014-07-16
CN101983071A (zh)	2011-03-02
PL2268310T3 (pl)	2017-08-31
HUE028828T2 (en)	2017-01-30
CL2009000713A1 (es)	2010-04-09
AU2009228616A1 (en)	2009-10-01
SI2268310T1 (sl)	2016-11-30
PE20091821A1 (es)	2009-11-25
US20160000911A1 (en)	2016-01-07
RS55258B1 (sr)	2017-02-28
NZ587284A (en)	2012-05-25
JP5912142B2 (ja)	2016-04-27
CR11687A (es)	2011-01-10
US20100310581A1 (en)	2010-12-09
HRP20161301T1 (hr)	2016-11-18
IL208018A0 (en)	2010-12-30
CA2716884C (en)	2017-10-03
JP2011515428A (ja)	2011-05-19
CA2716884A1 (en)	2009-10-01
EP2268310B1 (en)	2016-07-20
JP6154039B2 (ja)	2017-06-28
US20090246197A1 (en)	2009-10-01
AR072947A1 (es)	2010-10-06
US20110177067A1 (en)	2011-07-21
CN107198772A (zh)	2017-09-26
TWI500624B (zh)	2015-09-21
TW200951141A (en)	2009-12-16
WO2009118142A1 (en)	2009-10-01
PT2268310T (pt)	2016-08-23
MY163544A (en)	2017-09-29
RU2010143454A (ru)	2012-05-10
US20120301459A1 (en)	2012-11-29
MA32140B1 (fr)	2011-03-01
DK2268310T3 (en)	2016-08-15
KR101280716B1 (ko)	2013-07-01
ZA201006190B (en)	2018-11-28
US20140065134A1 (en)	2014-03-06
IL208018A (en)	2017-12-31
BRPI0909227B1 (pt)	2020-11-24
EP2268310A1 (en)	2011-01-05
LT2268310T (lt)	2016-09-26
KR20100121525A (ko)	2010-11-17
JP2016121183A (ja)	2016-07-07
RU2589704C2 (ru)	2016-07-10
MX2010009647A (es)	2010-09-28
CY1117984T1 (el)	2017-05-17
ES2592312T3 (es)	2016-11-29
BRPI0909227B8 (pt)	2021-05-25

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-06-18	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2020-04-07	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-09-29	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-11-24	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
BRPI0909227A2 (pt)	2015-12-01	uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin.
WO2009086471A3 (en)	2009-09-11	Synergistic antiparasitic compositions and screening methods
BRPI0722259A2 (pt)	2014-04-08	Método para produção de um vestuário absorvente, e vestuário absorvente produzido de acordo com o método
WO2008003007A3 (en)	2008-05-22	Compositions and methods for treating parasitic infections
BRPI0814420A2 (pt)	2015-11-17	composição, e, uso de álcool alcoxilado.
MX373050B (es)	2020-05-21	Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojos.
CR11274A (es)	2010-05-31	Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
BRPI0812005A2 (pt)	2019-09-24	anticorpos humanizados para o globulômeros de ab(20-42) e seus usos.
BRPI0819047A2 (pt)	2015-05-05	"composição, seu processo de preparação e seus usos"
BRPI0813680A2 (pt)	2015-01-06	AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
BRPI0808098A2 (pt)	2014-06-17	4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BRPI0718688A2 (pt)	2013-12-24	Composições de baixa irritação e métodos para preparar as mesmas.
BRPI0813627A2 (pt)	2014-12-23	Peptídio antimicrobiano, composições e métodos de uso
BRPI0921249A2 (pt)	2018-10-23	uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer.
BRPI0908503A2 (pt)	2015-09-29	partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0814692A2 (pt)	2015-01-20	Mistura sinergística, uso da mistura sinergística, material orgânico inanimado, composição de combustível, concentrado de aditivo, e, composição lubrificante
WO2009026282A3 (en)	2009-09-03	Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin b receptor agonist
BRPI0912292A2 (pt)	2015-10-20	composições e métodos para o uso de células no tratamento do tecido cardíaco.
CL2008001069A1 (es)	2008-08-08	Compuestos derivados de tetrahidroindazoles y tetrahidroindoles; procedimiento de preparacion; y su uso para tratar una enfermedad o trastorno relacionado con la proliferacion celular.
BRPI0808172A2 (pt)	2014-11-04	Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
BRPI0814931A2 (pt)	2015-02-03	Composto com atividade contra hcv, sua composição e seu uso
BRPI0815768A2 (pt)	2014-09-30	Uso de absorventes de uv, e, composição cosmética.
BRPI0810560A2 (pt)	2014-10-07	Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida.
BRPI0821025A2 (pt)	2014-11-04	Método para tratar biomassa, método para produzir biotanol, uso da composição e biomassa processada.
BR112012002490A2 (pt)	2016-11-22	composição limpadora com baixa irritabilidade, composição concentrada e seu uso